文献速递眼底病与葡萄膜炎

两端口免玻璃体切割视网膜下基因治疗用于Bietti结晶样营养不良

Two-Port Vitrectomy-free Subretinal Gene Therapy for Bietti Crystalline Dystrophy.
PubMed 文献 · Retina · 2026-06-10

该研究评估了一种改良两端口、免玻璃体切割的视网膜下注射技术,用于Bietti结晶样营养不良患者的基因治疗。19例患者接受该手术,术中无并发症,手术时间9至14分钟,随访至2年,6个月时79%患眼视力改善,未观察到白内障形成,结论认为该技术可行且安全,但需对照研究确认。

要点

  • 两端口免玻璃体切割视网膜下注射技术可行,19例手术均无术中并发症。
  • 术后6个月79%患眼视力改善,1年61%,2年50%。
  • 随访期间未观察到白内障形成。

核心结论

  • 该简化的免玻璃体切割视网膜下递送技术看起来可行且安全。
  • 该方法可能降低早期白内障风险,但观察结果仍为初步,需对照研究和更长随访确认。

研究设计与样本

  • 研究纳入19例Bietti结晶样营养不良患者,采用两端口、免玻璃体切割手术方式行视网膜下基因递送。
  • 通过前房穿刺控制眼压,随访至2年,监测免疫反应、视网膜完整性、白内障形成和视力变化。

主要发现

  • 患者年龄32至62岁(平均44±8岁),男性10例。
  • 所有手术均无术中并发症完成,手术时间9至14分钟。
  • 视网膜下液泡在18眼于4小时内吸收,1眼于72小时内吸收,后者卧床休息后延迟吸收。
  • 随访期间未观察到白内障形成。
  • 视力改善比例:6个月时为15/19眼(79%),1年时为11/18眼(61%),2年时为5/10眼(50%)。

临床怎么用

  • 该技术可为Bietti结晶样营养不良患者提供免玻璃体切割的视网膜下基因递送选择,可能减少早期白内障风险。
  • 术后需监测视网膜下液泡吸收情况,延迟吸收者可考虑卧床休息。
  • 长期视力获益需对照研究进一步确认。

局限性

  • 观察结果仅为初步,需要对照研究和更长随访确认。
  • 样本量较小,随访至2年时视力数据仅10眼。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and feasibility of a modified two-port, vitrectomy-free subretinal injection technique for gene therapy in patients with Bietti crystalline dystrophy. METHODS: Nineteen patients with Bietti crystalline dystrophy underwent subretinal gene delivery using a two-port, vitrectomy-free surgical approach. Intraocular pressure was controlled via anterior chamber paracentesis. Patients were monitored for immune response, retinal integrity, cataract development, and visual changes during follow-up up to 2 years. RESULTS: The patients' ages ranged from 32 to 62 years (mean, 44±8 years, 10 males). All procedures were completed without intraoperative complications. The surgery time ranged from 9 to 14 minutes. Subretinal bleb resolved within 4 hours in 18 eyes and 72 hours in one eye, with delayed resolution after bed rest. No cataract formation was observed during follow-up. Visual acuity improved in 15 of 19 eyes (79%) at 6 months, 11 of 18 eyes (61%) at 1 year, and 5 of 10 eyes (50%) at 2 years. Three eyes (3/10, 30%) with visual decline at 2 years were not associated with cataract formation. CONCLUSIONS: This simplified, vitrectomy-free subretinal delivery technique appears feasible and safe. This approach may reduce early cataract risk; however, these observations remain preliminary and require confirmation in comparative studies with longer follow-up.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Chen X, Luo X, Li X, et al. Two-Port Vitrectomy-free Subretinal Gene Therapy for Bietti Crystalline Dystrophy. Retina. 2026. PMID: 42267952. doi:10.1097/IAE.0000000000004905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。